Coenzyme Q10: uses, evidence, dosing and safety

Coenzyme Q10 is an unusual case in the supplement aisle: the evidence is better than average, and it is almost entirely for a condition the people buying it do not have.

Most CoQ10 is sold to people on statins who have aching legs. The evidence there is weak. The evidence in heart failure, a diagnosed condition managed in a clinic, is the strongest thing this compound has, and it is not what the shelf is selling.

What coenzyme Q10 is

CoQ10 is not a vitamin, because the body makes it. NCCIH describes it as a substance that is naturally present in the human body, with the highest levels in the heart, liver, kidneys, and pancreas.

Those locations are the clue. It concentrates in tissues that never stop working, because its job is inside the mitochondria, the compartments that generate a cell’s energy.

It is sold in two forms, ubiquinone and ubiquinol, which matters commercially and is covered below.

How coenzyme Q10 works

CoQ10 shuttles electrons along the chain that produces cellular energy, and separately acts as a fat-soluble antioxidant inside cell membranes.

Two consequences follow, and both drive the marketing. Levels fall with age. And statins, which block an early step in cholesterol synthesis, block the same pathway the body uses to make CoQ10, so statin users have lower levels.

That second fact is the entire basis of the statin muscle pain claim. It is a genuinely good hypothesis. It is also, as the trials below show, one that did not survive testing.

There is a flip side to that reasoning worth noting: coenzyme Q10 deficiency may be associated with a multitude of diseases, including heart failure.

What the evidence says about CoQ10 and heart failure

This is the strongest evidence for any supplement on this site, and it is worth stating carefully because it applies to a narrow group.

The 2021 Cochrane review found that the included studies provide moderate-quality evidence that coenzyme Q10 probably reduces all-cause mortality and hospitalisation for heart failure.

Moderate-quality evidence of a mortality benefit is rare in this category. Cochrane is equally clear about the limits of the rest: there is low-quality evidence of inconclusive results as to whether coenzyme Q10 has an effect on the risk of myocardial infarction, or stroke, meaning heart attack, and because of very low-quality evidence, it is very uncertain whether coenzyme Q10 has an effect on either left ventricular ejection fraction or exercise capacity - ejection fraction meaning the share of blood the main pumping chamber pushes out with each beat.

So the pump does not measurably work better. People just die and go to hospital less, which is the outcome that matters most and the mechanism nobody can yet explain.

The trial underneath it

Most of that conclusion rests on one two-year randomized trial. Q-SYMBIO reported cardiovascular mortality (9% vs. 16%) and all-cause mortality (10% vs. 18%) lower on CoQ10, along with the incidence of hospital stays for HF. It also found a significant improvement of NYHA class, meaning the standard scale of how limited a patient is by symptoms.

Its conclusion is that long-term CoQ10 treatment of patients with chronic HF is safe, improves symptoms, and reduces major adverse cardiovascular events.

One trial carrying a Cochrane conclusion is a caveat in itself. It is a good trial, and the finding needs replication before anyone treats it as settled.

What the evidence says about coenzyme Q10 and statin muscle pain

This is what most buyers want, and it is where the evidence goes cold.

A retrospective analysis of a large, multicenter survey study of SAMS, meaning statin-associated muscle symptoms, covered 511 people, of whom 64 were taking CoQ10.

The frequency of SAMS resolution was similar between CoQ10 users and non-users (25% vs 31%. If anything the supplement users did slightly worse, and the range around that difference comfortably includes no effect.

The mechanism was sound and the result did not follow it. That happens often enough that it should be the default expectation rather than a surprise.

If statin muscle symptoms are the problem, the productive conversation is with the prescriber about dose, timing or switching statin, not with a supplement shelf.

What the evidence says about coenzyme Q10 and blood pressure

Short section, because the answer is short.

A Cochrane review provides moderate-quality evidence that coenzyme Q10 does not have a clinically significant effect on blood pressure, meaning no change large enough to matter to a patient.

The reviewers add the usual caution, that due to the small number of individuals and studies available for analysis, more well-conducted trials are needed. Moderate-quality evidence of no effect is still evidence of no effect.

Myths about coenzyme Q10, and what the evidence says

“Everyone on a statin should take it.” Statins do lower CoQ10, and correcting that has not been shown to resolve the muscle symptoms it was supposed to explain.

“Ubiquinol is the superior form.” It absorbs better. No trial shows that better absorption produces better outcomes, and the trial behind the heart failure result used the cheaper form.

“It boosts energy.” It is central to energy production in cells, which is not the same as making a person feel less tired. No good evidence supports it for fatigue in people who are not deficient.

“It lowers blood pressure.” Cochrane says otherwise, at moderate quality.

“It is an antioxidant, so it must protect the heart.” In heart failure something protective does seem to happen. In people without heart failure, that has not been demonstrated.

Dosing and forms of coenzyme Q10

The heart failure trials used around 300 mg a day, usually split across doses, which is higher than most retail products.

Absorption is poor and improves with food containing fat, which is why it is normally taken with a meal.

On forms: ubiquinone is the conventional, cheaper, and more studied version, and it is what Q-SYMBIO used. Ubiquinol is the reduced form with better measured absorption and a higher price. Choosing on absorption alone means paying for a laboratory advantage that has never been attached to an outcome.

Safety, side effects and who should avoid CoQ10

The safety picture is good. Trials report mild gastrointestinal complaints, and Q-SYMBIO concluded that long-term CoQ10 treatment of patients with chronic HF is safe across two years.

The interaction is the part to take seriously. CoQ10 resembles vitamin K structurally and can blunt the effect of warfarin, which means a change in clotting control rather than an upset stomach. Anyone taking warfarin should not start it without telling the clinician who manages their dosing.

For the same reason it is usually stopped before surgery. And because the heart failure evidence concerns treatment of a diagnosed condition, nobody should be self-managing heart failure with a supplement.

Interactions

Warfarin is the clinically important one, described above.

Beyond that, blood pressure and diabetes medications are commonly listed as theoretical interactions on the grounds that CoQ10 might add to their effect. Given that the blood pressure evidence shows no clinically meaningful change, that concern is weaker than it sounds, but it is still worth raising with a pharmacist.

Bottom line on coenzyme Q10

If you have diagnosed heart failure, this is the rare supplement with moderate-quality evidence behind a mortality benefit, and it is a conversation to have with your cardiologist rather than a decision to make in a shop.

If you are on a statin with aching muscles, the evidence does not support it, and the person who can actually help is the one who wrote the prescription.

If you are taking it for energy, blood pressure or general antioxidant protection, you are buying a mechanism rather than a result.

And if you are choosing between ubiquinol and ubiquinone, the trial that produced the good news used the cheap one.